Are there patients with T1 to T2, lymph node-negative breast cancer who are "high-risk" for locoregional disease recurrence? Academic Article uri icon


MeSH Major

  • Breast Neoplasms
  • Carcinoma, Ductal, Breast
  • Carcinoma, Lobular
  • Lymph Nodes
  • Mastectomy
  • Neoplasm Recurrence, Local
  • Neoplasms, Multiple Primary


  • In the current study, a low crude LRR rate (4.7%) was observed in a large unselected cohort of patients with T1 to T2N0 breast cancer with high-risk features who were treated with mastectomy and systemic therapy without PMRT. Although increasing tumor size and the omission of systemic therapy were found to be predictive, other features did not confer a higher LRR risk either independently or together, and do not by themselves mandate the use of PMRT in this patient population. Cancer 2017. © 2017 American Cancer Society.

publication date

  • January 2017



  • Academic Article



  • eng

PubMed Central ID

  • PMC5498246

Digital Object Identifier (DOI)

  • 10.1002/cncr.30658

PubMed ID

  • 28334423

Additional Document Info